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Abstract
Background/aims: The renin-angiotensin system (RAS) is altered in Parkinson’s disease (PD), a disease due to
substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa,
leads to dyskinesias as the main side effect. Angiotensin AT1 and AT2 receptors, mainly known for their role in
regulating water homeostasis and blood pressure and able to form heterodimers (AT1/2Hets), are present in the
central nervous system. We assessed the functionality and expression of AT1/2Hets in Parkinson disease (PD).
Methods: Immunocytochemistry was used to analyze the colocalization between angiotensin receptors;
bioluminescence resonance energy transfer was used to detect AT1/2Hets. Calcium and cAMP determination, MAPK
activation, and label-free assays were performed to characterize signaling in homologous and heterologous
systems. Proximity ligation assays were used to quantify receptor expression in mouse primary cultures and in rat
striatal sections.
Results: We confirmed that AT1 and AT2 receptors form AT1/2Hets that are expressed in cells of the central nervous
system. AT1/2Hets are novel functional units with particular signaling properties. Importantly, the coactivation of the
two receptors in the heteromer reduces the signaling output of angiotensin. Remarkably, AT1/2Hets that are
expressed in both striatal neurons and microglia make possible that candesartan, the antagonist of AT1, increases
the effect of AT2 receptor agonists. In addition, the level of striatal expression increased in the unilateral 6-OH-
dopamine lesioned rat PD model and was markedly higher in parkinsonian-like animals that did not become
dyskinetic upon levodopa chronic administration if compared with expression in those that became dyskinetic.
Conclusion: The results indicate that boosting the action of neuroprotective AT2 receptors using an AT1 receptor
antagonist constitutes a promising therapeutic strategy in PD.
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Introduction
The renin angiotensin system (RAS) is composed of
enzymes that produce angiotensin (Ang) peptides and of
cell surface receptors that convey cytocrin signals to achieve
specific cell responses. There are two angiotensin receptors
(AT1R and AT2R) that belong to the superfamily of G-
protein-coupled receptors. RAS has been abundantly stud-
ied in the periphery, mainly in relation with the control of
arterial blood pressure. However, different laboratories have
provided solid evidence of the relevant role of RAS in the
central nervous system (CNS). Ang is an important regula-
tor of motor control, and AT1R and AT2R have been
suggested as targets to combat Parkinson’s disease (PD)
and related conditions such as levodopa (L-DOPA)-induced
dyskinesias [38, 45].
Age is a main risk factor for sporadic PD, which is char-
acterized by dysregulation of the dopaminergic function
due to the death of dopaminergic neurons of the substan-
tia nigra (SN). A local RAS has been reported in the SN
[20, 61], in which overactivity of AT1R correlates with
aging-related alterations, neuronal death [22, 31], and
neuroinflammation (Labandeira-Garcia et al., [29, 30, 52]).
Microglial cells are the main mediators of neuroinflamma-
tion and despite once activated they are considered as det-
rimental, it is now known that they may undertake the
pro-inflammatory (M1) or the neuroprotective (M2)
phenotype. The search for pharmacological tools targeting
G-protein-coupled receptors to convert M1 into M2
phenotype is an active field of research. The role of AT2R
and the interplay between the two receptors in the above-
mentioned changes due to Ang action in the aged or in
the pathological brain is still unclear.
The cognate proteins for coupling to AT1R and AT2R
are, respectively, Gq (also Gi) and Gi. Accordingly, ago-
nists of AT1R may mobilize calcium ion from intracellular
stores, whereas agonists of AT2R decrease the activity of
adenylyl cyclase thus depressing the cAMP/PKA signaling
(https://www.guidetopharmacology.org). Interestingly, the
two receptors may interact, leading to the formation of
receptor heteromers with particular properties: pharmaco-
logical, functional, or both [15, 48]. On the one hand, het-
eromerization modifies receptor trafficking and ß-arrestin
recruitment [48]. On the other hand, Ang II induces the
formation of heteromers of the two receptors (AT1/2Hets)
in luminal membranes of kidney tubular epithelial
LLC-PK1 cells. In these cells, the peptide activates a cal-
cium channel, sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA), that in kidney cells participates in the control of
blood pressure [14].
The main target for pharmacological anti-parkinsonian
interventions is the striatum that receives the SN dopa-
minergic input needed for motor control. What is
important is to know whether AT1 and AT2 receptors
interact in the CNS, which is their physiological function
and how their expression alters the course of a neurode-
generative disease. Accordingly, the aims of this paper
were to (i) get further insight into the properties of
AT1/2Hets in a heterologous expression system; (ii) in-
vestigate the expression and function of AT1R, AT2R,
and AT1/2Hets in striatal neurons; and (iii) investigate
the expression and function of AT1R, AT2R, and
AT1/2Hets in striatal microglia in resting and activated
states. The results show that AT2R are expressed in neu-
rons and in activated microglia where they interact with
AT1R to form AT1/2Hets. Accordingly, a final aim was
to discover differential expression of AT1/2Hets in stri-
atal samples from parkinsonian and dyskinetic animals.
Materials and methods
Reagents
Lipopolysaccharide (LPS), interferon-γ (IFN-γ), and
forskolin, Angiotensin II (Ang II), CGP-42112A (CGP),
Candesartan (CAN) and PD123319 (PD) were purchased
from Sigma-Aldrich (St Louis, MO).
HEK-293T cells and primary cultures
Human embryonic kidney (HEK-293T) cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco)
supplemented with 2 mM L-glutamine, 100 μg/mL so-
dium pyruvate, 100 U/mL penicillin/streptomycin, MEM
non-essential amino acids solution (1/100), and 5% (v/v)
heat-inactivated fetal bovine serum (FBS) (all supplements
were from Invitrogen, Paisley, Scotland, UK).
To prepare mouse striatal primary microglial cultures,
brain was removed from C57BL/6 mice of 2–4 days of
age. Microglial cells were isolated following protocols
described elsewhere [40, 49, 56] and grown in DMEM
medium supplemented with 2 mM L-glutamine, 100 U/
mL penicillin/streptomycin, MEM non-essential amino
acids preparation (1/100), and 5% (v/v) heat-inactivated
FBS (Invitrogen, Paisley, Scotland, UK). Briefly, striatum
tissue was dissected, carefully stripped of its meninges,
and digested with 0.25% trypsin for 20 min at 37 °C. The
action of the proteolytic enzyme was stopped by adding
an equal volume of culture medium (Dulbecco’s modi-
fied Eagle medium-F-12 nutrient mixture, fetal bovine
serum 10%, penicillin 100 U/mL, streptomycin 100 μg/
mL, and amphotericin B 0.5 μg/mL) with 160 μg/mL
deoxyribonuclease I (all reagents from Invitrogen). Cells
were brought to a single cell suspension by repeated pip-
etting followed by passage through a 100 μm-pore mesh
and pelleted (7 min, 200×g). Glial cells were resuspended
in medium and seeded at a density of 3.5 × 105 cells/mL
in 6-well plates for cyclic adenylic acid (cAMP) assays,
in 12-well plates with coverslips for in situ proximity
ligation assays (PLA), and in 96-well plates for mitogen-
activated protein kinase (MAPK) activation experiments.
Cultures were maintained at 37 °C in humidified 5%
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CO2 atmosphere and medium was replaced at DIV 2
and then once a week. At DIV 19-21 cells were treated
with diluted trypsin [56] to obtain > 98% pure microglial
cultures.
For neuronal primary cultures, the striatum from mouse
embryos (E19) was removed and the neurons were isolated
as described by [25] and plated at a density of circa 120,
000 cells/cm2. The cells were grown in a neurobasal
medium supplemented with 2 mM L-glutamine, 100 U/mL
penicillin/streptomycin, and 2% (v/v) B27 supplement
(Gibco) in a 6-, 12-, or 96-well plate for 19–21 days.
Cultures were maintained at 37 °C in humidified 5% CO2
atmosphere and medium was replaced every 4–5 days.
Immunodetection of specific markers (NeuN for
neurons and CD-11b for microglia) showed that neuronal
preparations contained > 98% neurons and microglia
preparations contained, at least, 98% microglial cells [39].
Parkinson’s disease model generation, levodopa
treatment, and dyskinesia assessment
All experiments were carried out in accordance with EU
directives (2010/63/EU and 86/609/CEE) and were
approved by the Ethical committee of the University of
Santiago de Compostela. Similar to the approach
elsewhere described [13], an experimental design using
male Wistar rats was aimed at obtaining four group of
animals as described below. Animals were 8-week-old at
the beginning of the experimental procedure.
Details of model generation, protocol of drug adminis-
tration, and behavioral analysis, performed by a blinded
investigator, are given elsewhere [38, 47]. Surgery was
performed on rats anesthetized with ketamine/xylazine
(1% ketamine—75 mg/kg, and 2% xylazine—10 mg/kg).
Lesions were produced in the right medial forebrain
bundle to achieve complete lesion of the nigrostriatal
pathway. The rats were injected with 12 μg of 6-OH-DA
(to provide 8 μg of 6-hydroxy-DA free base; Sigma-
Aldrich) in 4 μL of sterile saline containing 0.2% ascorbic
acid. These were considered “lesioned” animals. Injection
of vehicle lead to generation of naïve (or non-lesioned)
animals.
The 6-OH-dopamine hemilesioned rat is considered a
PD model. Amphetamine-induced rotation was tested in
a bank of eight automated rotometer bowls (Rota-count
8, Columbus Instruments, Columbus, OH, USA) by
monitoring full (360°) body turns in either direction.
Right and left full body turns were recorded over 90 min
following an injection of D-amphetamine (2.5 mg/kg i.p.)
dissolved in saline. Rats that displayed more than six full
body turns/min ipsilateral to the lesion were included in
the study (this rate would correspond to more than 90%
depletion of dopamine fibers in the striatum) [65].
Spontaneous use of forelimb can be measured by the
cylinder test [28, 57]. Rats were placed individually in a
glass cylinder (20 cm in diameter), and the number of
left or right forepaw contacts were scored by an observer
blinded to the animals’ identity and presented as left
(impaired) touches in percentage of total touches. A
control animal would thus receive an unbiased score of
50%, whereas lesion usually reduces performance of the
impaired paw to less than 20% of total wall contacts.
Of the lesioned animals displaying parkinsonism-like
behavior according to the above described tests (18 in
total), 12 were chronically treated with L-DOPA daily for
3 weeks. A mixture of L-DOPA methyl ester (6 mg/kg)
plus benserazide (10 mg/kg) was subcutaneously admin-
istered. The treatment reliably induces dyskinetic move-
ments in some rats. As described in a previous report
[13], abnormal involuntary movements (AIMs) were
evaluated according to the rat dyskinesia scale described
in detail elsewhere [5, 12, 33, 36, 47]. The severity of
each AIM subtype (limb, orolingual, and axial) was
assessed using scores from 0 to 4 (1, occasional, i.e.,
present < 50% of the time; 2, frequent, i.e., present > 50%
of the time; 3, continuous, but interrupted by strong
sensory stimuli; 4, continuous, not interrupted by strong
sensory stimuli). Rats were classified as “dyskinetic” if
they displayed a ≥ 2 score per monitoring period on at
least two AIM subtypes. Animals classified as “non-dys-
kinetic” exhibited either no L-DOPA-induced abnormal
involuntary movements or very mild/occasional ones
[41]. Animals with low scores, i.e., either non-dyskinetic
or dyskinetic, were discarded. In summary, four groups
of animals were obtained: (i) non-lesioned, (ii) lesioned
treated with vehicle, (iii) lesioned L-DOPA-treated be-
coming dyskinetic, and (iv) lesioned that upon L-DOPA
treatment did not become dyskinetic. In every animal,
tyrosine hydroxylase immunostaining was performed in
sections taken post-mortem [19, 38]; selected animals
undergoing 6-OH-dopamine treatment showed in the le-
sioned hemisphere a > 95% nigral dopaminergic denerv-
ation. Overall, 4 animals, those with better scores, were
selected in each of following 4 groups: naïve, lesioned,
lesioned/L-DOPA dyskinetic, and lesioned/L-DOPA non
dyskinetic. PLA analysis (see below) was performed in
different fields of striatal sections from each of the 16 fi-
nally selected animals. The striatum was delimited in sec-
tions using a bright field and images were captured within
delimitation coordinates.
Fusion proteins
Human cDNAs for AT1, AT2, and σ1 receptors cloned
into pcDNA3.1 were amplified without their stop codons
using sense and antisense primers harboring either
BamHI and HindIII restriction sites to amplify AT1R
and AT2R or BamHI and EcoRI restriction sites to
amplify σ1 receptor. Amplified fragments were then
subcloned to be in frame with an enhanced yellow
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fluorescent protein (pEYFP-N1; Clontech, Heidelberg,
Germany) or a Rluc (pRluc-N1; PerkinElmer, Wellesley,
MA) on the C-terminal end of the receptor to produce
AT1R-YFP, AT2R-RLuc, AT2R-YFP, and σ1R-RLuc
fusion proteins.
Cell transfection
HEK-293T cells were transiently transfected with the
corresponding cDNA by the polyethylenimine (PEI,
Sigma-Aldrich, St. Louis, MO) method [18, 23]. Briefly,
the corresponding cDNA diluted in 150 mM NaCl was
mixed with PEI (5.5 mM in nitrogen residues) also
prepared in 150 mM NaCl for 10 min. The cDNA-PEI
complexes were transferred to HEK-293T cells and were
incubated for 4 h in a serum-starved medium. Then, the
medium was replaced by fresh supplemented culture
medium and cells were maintained at 37 °C in a humid
atmosphere of 5% CO2. Forty-eight hours after transfec-
tion, cells were washed, detached, and resuspended in
the assay buffer.
Immunocytochemistry
HEK-293T cells were seeded on glass coverslips in 12-well
plates. On DIV 2, cells were transfected with AT1R-YFP
cDNA (1 μg), AT2R-Rluc cDNA (1 μg), or both. On DIV
4, cells were fixed in 4% paraformaldehyde for 15 min and
washed twice with PBS containing 20 mM glycine before
permeabilization with PBS-glycine containing 0.2% Triton
X-100 (5-min incubation). Cells were blocked during 1 h
with PBS containing 1% bovine serum albumin. HEK-
293T cells were labeled with a mouse anti-Rluc antibody
(1/100; Millipore, Darmstadt, Germany) and subsequently
treated with Cy3 conjugated anti-mouse (1/200; Jackson
ImmunoResearch (red)) IgG (1 h each). The AT1R-YFP
expression was detected by YFP’s own fluorescence. Con-
trols using untransfected cells and cells incubated without
the primary antibody are shown in Supplementary Figure
S1. Samples were washed several times and mounted with
30% Mowiol (Calbiochem). Images were obtained in a
Leica SP2 confocal microscope (Leica Microsystems) with
the × 63 oil objective.
Bioluminescence resonance energy transfer assays
For bioluminescence resonance energy transfer (BRET)
assays, HEK-293T cells were transiently cotransfected
with a constant amount of cDNA encoding for AT2R-
RLuc (0.9 μg) and with increasing amounts of cDNA
corresponding to AT1R-YFP (0.5 to 4 μg). For negative
control, HEK-293T cells were transiently cotransfected
with a constant amount of cDNA encoding for σ1-RLuc
(0.75 μg) and with increasing amounts of cDNA corre-
sponding to AT2R-YFP (0.1 to 4 μg). To control the cell
number, sample protein concentration was determined
using a Bradford assay kit (Bio-Rad, Munich, Germany)
using bovine serum albumin (BSA) dilutions to prepare
the standard absorbance versus concentration relation-
ship. To quantify fluorescent proteins, cells (20 μg protein)
were distributed in 96-well microplates (black plates with
a transparent bottom) and fluorescence was read in a
Fluostar Optima Fluorimeter (BMG Labtech, Offenburg,
Germany) equipped with a high-energy xenon flash lamp,
using a 10 nm bandwidth excitation filter at 485 nm. For
BRET measurements, the equivalent of 20 μg of cell sus-
pension was distributed in 96-well white microplates with
white bottom (Corning 3600, Corning, NY) and 5 μM coe-
lenterazine H (Molecular Probes, Eugene, OR) was added.
One minute after adding coelenterazine H, BRET was
determined using a Mithras LB 940 reader (Berthold
Technologies, DLReady, Germany), which allows the inte-
gration of the signals detected in the short-wavelength
filter at 485 nm and the long-wavelength filter at 530 nm.
To quantify AT2R-RLuc expression, luminescence read-
ings were performed 10 min after the addition of 5 μM
coelenterazine H. MilliBRET units (mBU) are defined as:
mBU ¼ λ530 long −wavelength emissionð Þ
λ485 short −wavelength emissionð Þ −C f
 
x 1000
where Cf corresponds to [(long-wavelength emission)/
(short-wavelength emission)] for the RLuc construct
expressed alone in the same experiment.
Detection of cytoplasmic calcium ion
HEK-293T cells were cotransfected with the cDNA for
the Ang receptors AT1 (1 μg) and/or AT2 (1 μg) and the
GCaMP6 calcium sensor (1 μg) [11] by the use of PEI
method (Section “Cell Transfection”). Forty-eight hours
post-transfection, HEK-293T cells plated in 6-well black,
clear bottom plates, were incubated with Mg2+-free
Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM
NaHCO3, 2.3 mM CaCl2, 5.6 mM glucose, 5 mM HEPE
S, pH 7.4) supplemented with 10 μM glycine. Receptor
antagonists were added only 15 min before readings to
allow efficient binding to receptors while avoiding
unspecific or long-term noxious events. Receptor ago-
nists were added right before readings as calcium level
increase when mediated by Gq-coupled receptors is very
quick. Fluorescence emission intensity of GCaMP6 was
recorded at 515 nm upon excitation at 488 nm on the
EnSpire® Multimode Plate Reader for 150 s every 5 s at
100 flashes per well.
cAMP level determination
The analysis of cAMP levels was performed in HEK-
293T cells transfected with cDNA for AT1 (1 μg) and/or
AT2 (1 μg) receptors in primary cultures of striatal
neurons or glia using the Lance Ultra cAMP kit
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(PerkinElmer). The optimal cell density to obtain an
appropriate fluorescent signal was first established by
measuring the TR-FRET signal as a function of forskolin
concentration using different cell densities. Forskolin
dose-response curves were related to the cAMP standard
curve in order to establish which cell density provides a
response that covers most of the dynamic range of
cAMP standard curve. Two hours before the experiment,
the medium was substituted by serum-starved DMEM
medium. Cells (2000 HEK-293T cells, 4000 striatal neu-
rons, or glial cells by well in 384-well microplates) growing
in medium containing 50 μM zardaverine were pre-
treated with the AT1R or AT2R antagonists (Candesartan
and PD123319 respectively) or the corresponding vehicle
at 24 °C for 15 min, and stimulated with the AT1R and/or
AT2R agonists (Ang II and CGP-42112A respectively) for
15 min before adding 0.5 μM forskolin or vehicle, and
incubating for an additional 15-min period. After 1 h,
fluorescence at 665 nm was analyzed on a PHERAstar
Flagship microplate reader equipped with an HTRF
optical module (BMG Labtech). A standard curve for
cAMP was obtained in each experiment.
Extracellular signal-regulated kinases 1/2 phosphorylation
To determine extracellular signal-regulated kinases 1/2
(ERK1/2) phosphorylation, 40,000 HEK-293T cells trans-
fected with cDNA for AT1R (1 μg) and/or AT2R (1 μg)
or 50,000 striatal neurons or glial cells primary cultures
were plated in each well of transparent Deltalab 96-well
microplates. Two hours before the experiment, the
medium was substituted by serum-starved DMEM
medium. Then, cells were treated or not for 15 min with
the selective antagonists Candesartan or PD123319 in
serum starved DMEM medium followed by 7-min treat-
ment with the selective agonists Ang II and/or CGP-
42112A. Cells were then washed twice with cold PBS
before the addition of lysis buffer (15-min treatment).
Ten microliters of each supernatant were placed in white
ProxiPlate 384-well microplates and ERK1/2 phosphor-
ylation was determined using AlphaScreen®SureFire® kit
(Perkin Elmer) following the instructions of the supplier
and using an EnSpire® Multimode Plate Reader (Perki-
nElmer, Waltham, MA, USA).
Dynamic mass-redistribution label-free assays
Cell signaling was explored using an EnSpire® Multi-
mode Plate Reader (PerkinElmer, Waltham, MA, USA)
by a label-free technology. Cellular cytoskeleton redistri-
bution movement induced upon receptor activation were
detected by illuminating the underside of the plate with
polychromatic light and measured as changes in wave-
length of the reflected monochromatic light that is a
sensitive function of the index of refraction. The magni-
tude of this wavelength shift (in picometers) is directly
proportional to the amount of dynamic mass redistribu-
tion (DMR). To determine the label free-DMR signal,
10,000 HEK-293T cells transfected with cDNA for AT1R
(1 μg) and/or AT2R (1 μg) receptors or 10,000 striatal
neurons or glial cells primary cultures were plated on
each well of transparent 384-well fibronectin-coated
microplates to obtain 70–80% confluent monolayers,
and kept in the incubator for 24 h. Previous to the assay,
cells were washed twice with assay buffer (HBSS with 20
mM HEPES, pH 7.15, 0.1% DMSO) and incubated in the
reader for 2 h in 30 μL/well of assay buffer at 24 °C.
Hereafter, the sensor plate was scanned and a baseline
optical signature was recorded for 10 min before adding
10 μL of antagonists (Candesartan or PD123319)
dissolved in assay buffer, followed by the addition, 30
min later of 10 μL of selective agonists (Ang II and/or
CGP-42112A) also dissolved in assay buffer. DMR
responses induced by the agonist were monitored for a
minimum of 3600 s.
Proximity ligation assay
Detection in natural sources of clusters formed by AT1
and AT2 receptors was addressed in primary cultures of
glial cells and rat brain sections.
Rats were processed for histological analysis as it
follows. Animals were injected an overdose of chloral
hydrate and transcardial perfusion fixation quickly
undertaken using cold 4% paraformaldehyde in 0.1 M
phosphate buffer (PB), pH 7.4. Brains were removed,
washed, and cryoprotected in the same buffer containing
20% sucrose. Serial 40-μm-thick coronal sections were
then cut with a freezing microtome and those containing
the striatum were collected in cryoprotectant solution.
Cells were grown on glass coverslips, fixed in 4% para-
formaldehyde for 15 min, washed with PBS containing
20 mM glycine to quench the aldehyde groups, perme-
abilized with the same buffer containing 0.05% Triton
X-100 for 5 to 15 min, and washed with PBS.
Cells and sections were then similarly processed. After
1-h incubation at 37 °C with the blocking solution in a
pre-heated humidity chamber, samples were incubated
overnight at 4 °C with a mixture of a mouse monoclonal
anti-AT1R antibody (1/100, sc-515884, Santa Cruz
Biotechnology, Texas, USA), a rabbit monoclonal anti-
AT2R antibody (1/100, ab92445, Abcam, Cambridge,
UK), and Hoechst (1/100 from stock 1 mg/mL; Sigma-
Aldrich) to stain the nuclei. The antibodies were
validated following the method in the technical brochure
of the vendor with fairly similar results and also by im-
munofluorescence in HEK-293T cells (transfected versus
untransfected). Samples from KO animals were not
available for validation.
Cells or brain sections were further processed using
the proximity ligation assays (PLA) probes detecting
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primary antibodies (Duolink In Situ PLA probe Anti-
Mouse plus and Duolink In Situ PLA probe Anti-Rabbit
minus) (1/5 v:v for 1-hour at 37 °C). Ligation and ampli-
fication were done as indicated by the supplier (Sigma-
Aldrich) and cells were mounted using the mounting
medium 30% Mowiol (Calbiochem). To detect red dots
corresponding to AT1/2Hets, samples were observed in a
Leica SP2 confocal microscope (Leica Microsystems,
Mannheim, Germany) equipped with an apochromatic
× 63 oil-immersion objective (N.A. 1.4), and a 405 nm
and 561 nm laser lines. For each field of view, a stack of
two channels (one per staining) and 3 Z-planes with a
step size of 1 μm were acquired. The Andy’s Algorithm
[32], a specific ImageJ macro for reproducible and high-
throughput quantification of the total PLA foci dots and
total nuclei, was used for data analysis.
Statistical analysis
The data in graphs are the mean ± SEM. GraphPad
Prism software version 7 (San Diego, CA, USA) was used
for data fitting and statistical analysis. The test of
Kolmogorov-Smirnov with the correction of Lilliefors
was used to evaluate normal distribution and the test of
Levene to evaluate the homogeneity of variance. The
Student’s t test and one-way ANOVA were used for
comparing, respectively, two or > 2 means. When indi-
cated, Bonferroni’s method was used as a post-hoc test
for multiple comparisons. Significant differences were
considered when the p value was < 0.05.
Results
Functionality of AT1/2Hets in a heterologous expression
system
Interactions between AT1 and AT2 receptors have been
previously reported [14, 48]. Hence, we first investigated
whether in HEK-293T cells and in our assay conditions
AT1 and AT2 receptors may form heteromers. We ana-
lyzed the colocalization of angiotensin receptors at the
plasma membrane by using HEK-293T cells coexpres-
sing AT1R and AT2R fused to, respectively, the yellow
fluorescent protein (YFP) and Renilla luciferase (Rluc).
The proper traffic of fusion proteins to the cell mem-
brane was confirmed by immunocytochemical analysis
(Fig. 1a, b). The high degree of colocalization between
AT1R-YFP and AT2R-Rluc in the plasma membrane and
in the cytosol is shown in yellow (Fig. 1c). To know
whether a direct interaction between AT1 and AT2
receptors is possible, BRET assays were performed in
HEK-293T cells expressing a constant amount of a fu-
sion protein consisting of AT2R and Renilla Luciferase
(AT2R-Rluc) and increasing amounts of AT1R fused to
YFP (AT1R-YFP). The saturation curve in Fig. 1d indi-
cates close proximity between the two Ang receptors.
The BRETmax and BRET50 values were 42 ± 1 mBU and
6 ± 2, respectively. When HEK-293T cells were trans-
fected with a constant amount of cDNA for σ1-Rluc and
increasing amounts of cDNA for AT1R-YFP, a linear re-
sponse was observed indicating a nonspecific interaction
of this negative control (Fig. 1d). These results confirm
that the two Ang receptors may form heteromers in
living HEK-293T cells. The proper functionality of
fusion proteins was confirmed by cAMP assays (data not
shown). A schematic representation of the technique is
shown in Fig. 1e.
To characterize the AT1/2Het functionality, signaling
assays were performed in single-transfected HEK-293T
cells and in cotransfected AT1/2Hets-expressing cells.
Cytosolic calcium levels, cAMP determination, ERK1/2
phosphorylation, and label-free DMR assays were per-
formed after treatment with AT1R and/or AT2R ligands.
Consistent with Gq coupling of AT1R, treatment of
AT1R-expressing cells with Ang II led to a marked
increase in cytosolic calcium levels. The effect was
receptor-mediated, as it was blocked by candesartan, the
AT1R antagonist (Fig. 2a). In AT2R expressing cells, the
AT2R agonist CGP-42112A did not induce mobilization
of the ion. These results agree with AT2R not engaging
Gq proteins. In cotransfected cells, CGP-42112A did not
produce any effect but reduced the response peak pro-
duced by Ang II. Hence, within the AT1/2Het, AT2R
stimulation inhibits the AT1 receptor signaling. Unlike
the selective AT1R antagonist, candesartan, which blunted
the agonist effect, the selective AT2R antagonist, PD123319,
potentiated the AT1R-mediated effect (Fig. 2c).
Consistent with AT2R coupling to Gi, CGP-42112A
reduced the forskolin-induced cAMP cytosolic levels in
AT2R single transfected cells. Interestingly, in AT1R-ex-
pressing cells, Ang II treatment also reduced the
forskolin-induced cAMP levels. These effects can be
explained by AT1R coupling not only to Gq, but also to Gi
proteins. These effects were receptor-mediated and spe-
cific as they were blocked by the corresponding antagonist
(Fig. 2d, e). Analysis of cAMP-PKA signaling in cotrans-
fected cells is more complex. On the one hand, all agonists
reduced forskolin-induced [cAMP] and each antagonist
blocked the effect of the corresponding agonist. Simultan-
eous administration of Ang II and CGP-42112A did not
result in an additive effect. On the other hand, the antag-
onist of the AT2R enhanced the effect induced by the
AT1R agonist and vice-versa, the antagonist of the AT1R
enhanced the effect of the AT2R agonist (Fig. 2e). These
latter results fit with data from calcium release experi-
ments assays where the antagonist of the AT2R potenti-
ated the action of Ang II. Then, it seems that both
angiotensin receptors regulate one another via heteromer-
ization. The negative regulation can be reversed and the
antagonist of one receptor can even reinforce the output
due to activation of the partner receptor.
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In AT1R-expressing cells, a marked increase in agonist-
induced ERK1/2 phosphorylation that was blocked by
candesartan was observed, while in AT2R-expressing cells,
a mild non-significant effect was obtained by treatment
with the agonist, CGP-42112A (Fig. 3a, b). Remarkably,
AT1/2Hets expression in cotransfected cells led to a
significant increase in ERK1/2 phosphorylation upon Ang
II treatment. The selective AT2R agonist was still unable
to produce any significant effect but, in combined treat-
ments, it markedly reduced the effect induced by Ang II
(Fig. 3c). Therefore, these results are in the same line with
that observed in calcium release and cAMP accumulation,
indicating that both receptors inhibit one another in the
AT1/2Het.
DMR was modified by agonists in both types of single-
transfected cells. In AT1R-expressing cells, the antagonist
could not revert totally the effect of the agonist, indicating
that part of the output signal is due to off-site action of Ang
II (Fig. 3d). In contrast, the effect of CGP-42112A on AT2R-
expressing was totally blocked by PD123319 (Fig. 3e). In
cotransfected cells, the results indicate that both angiotensin
receptors show a characteristic signal that is blocked by
selective antagonists. However, coactivation in these cells
produced an important decrease in the signal. This effect is
named negative crosstalk and it is similar to that observed
in MAPK phosphorylation assays (Fig. 3e). The enhance-
ment by candesartan of the effect of CGP-42112A, the
AT2R agonist, was also noticed.
In summary, these results indicate a particular func-
tionality of the AT1/2Het, namely Ang is able to en-
gage two different signaling pathways. This dual effect
is regulated by activation of the partner receptor
within the AT1/2Het as (i) activation of AT1R blocks
AT2R agonist induced effect and vice-versa and (ii)
AT1R antagonist releases the inhibition exerted by
AT2R over AT1R and vice-versa.
Fig. 1 Human AT1 and AT2 receptors interact in a heterologous expression system. a–c Immunocytochemistry assays were performed in HEK-
293T cells expressing AT1R-YFP (1 μg cDNA), which was detected by its own yellow fluorescence (green), and AT2R-Rluc (1 μg cDNA), which was
detected by a mouse anti-Rluc antibody and a secondary Cy3 anti-mouse antibody (red). Colocalization is shown in yellow. Cell nuclei were
stained with Hoechst (blue). Scale bar: 20 μm. d BRET assays were performed in HEK-293T cells transfected with a constant amount of cDNA for
AT2R-Rluc (0.9 μg) or σ1R-Rluc (0.75 μg) (as negative control) and increasing amounts of cDNA for AT1R-YFP (0.5 to 4 μg) or AT2R-YFP (0.1 to 4 μg)
(as negative control). Values are the mean ± S.E.M. of 8 independent experiments performed in duplicates. e Schematic representation of BRET
assay: the occurrence of energy transfer depends on the distance between the BRET donor (Rluc) and the BRET acceptor (YFP)
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Functionality of AT1R and AT2R in primary
cultures of striatal neurons
On the basis of the above-described relevance of Ang re-
ceptors in motor control and as potential targets to combat
PD, we investigated Ang receptor-mediated signaling in
primary cultures of neurons isolated from mouse striatum.
Reduction of forskolin-induced [cAMP] was obtained
using Ang II, while no sign of Gi-coupled AT2R was de-
tectable (Fig. 4a). Interestingly, in simultaneous treatment
with agonists, the lower decrease of forskolin-induced
[cAMP] indicated the presence of AT2R whose activation
reduced AT2R-mediated signaling. In the presence of the
AT1R antagonist, candesartan, the AT2R agonist, CGP-
42112A, induced a significant decrease in forskolin-
induced cAMP levels (& in Fig. 4a). These results indicate
that in the AT1/2Het, the AT2R signal is inhibited by AT1R
expression and this effect is counteracted by AT1R antago-
nists. Similar results were confirmed in experiments of
ERK1/2 phosphorylation determination in cultured striatal
neurons, where cells responded (moderately) to Ang II and
non-significantly to CGP-42112A (Fig. 4b). However,
candesartan pretreatment potentiated AT2R signal. In
agreement with the results in HEK-293T cells, cotreatment
with agonists induced a lower signal to that induced by
angiotensin II, indicating a negative crosstalk effect in both
cAMP and MAPK phosphorylation signaling pathways.
Overall, these cells express AT1/2Hets with similar func-
tional characteristics to that observed in cotransfected
HEK-293T cells.
Functionality of AT1R and AT2R in primary cultures of
striatal microglia: expression of AT1/2Hets
Before assessing the functionality of Ang receptors in
resting and LPS + IFN-γ activated microglia isolated
from striatum, we used in situ PLA to assess the expres-
sion of AT1/2Hets; PLA is instrumental to detect clusters
of interacting proteins in natural sources. Figure 5b
shows that resting cells have a few number of red dots
due to AT1/2Hets, while the negative control show a
negligible number of red dots (Fig. 5a). Interestingly, the
Fig. 2 Functional characterization in HEK-293T cells expressing the AT1R-AT2R heteromer. HEK-293T cells were pretreated with selective receptor
antagonists (300 nM candesartan for AT1R or 1 μM PD123319 for AT2R) and subsequently treated with selective agonists (100 nM angiotensin II
for AT1R and 300 nM CGP-42112A for AT2R) a–c Cytosolic calcium detection assay were performed in HEK-293T cells transfected with the cDNAs
for an engineered calcium sensor, 6GCaMP (1 μg), AT1R (1 μg), and/or AT2R (1 μg). Values are the mean ± S.E.M. of 5 independent experiments
performed in duplicates. d–f Intracellular cAMP levels were determined by TR-FRET as described in Methods. HEK-293T cells were transfected with
cDNAs for AT1R (1 μg) and/or AT2R (1 μg). When Gi coupling was assessed, decreases in [cAMP] were determined using 0.5 μM forskolin added
15 min after the agonists stimulation. Values are the mean ± S.E.M. of 6 independent experiments performed in triplicates. In cAMP one-way
ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. Signaling output was the dependent
variable and the different treatments were the independent variables. (*p < 0.05, **p < 0.01, ***p < 0.001 versus forskolin treatment; +++p < 0.001
versus Ang II treatment; &&&p < 0.001 versus CGP-42112A treatment)
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Fig. 3 Functional characterization of AT1R-AT2R heteromer in HEK-293T cells. HEK-293T cells were transfected with cDNAs for AT1R (1 μg) and/or AT2R (1
μg). Cells were pretreated (15 min) with selective receptor antagonists (300 nM candesartan for AT1R or 1 μM PD123319 for AT2R receptors) and
subsequently treated with selective agonists (100 nM angiotensin II for AT1R and 300 nM CGP-42112A for AT2R receptors). a–c ERK1/2 phosphorylation was
analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer). Values are the mean ± S.E.M. of 5 independent experiments performed in duplicates. One-way
ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. Signaling output was the dependent variable and the
different treatments were the independent variables (*p < 0.05, **p < 0.01, ***p < 0.001; versus vehicle treatment (basal)). d–f DMR tracings represent the
picometer-shifts of reflected light wavelength over time. Values are the mean ± S.E.M. 8 independent experiments performed in triplicates
Fig. 4 AT1R-AT2R heteromer functionality in primary cultures of striatal neurons. For cAMP (a) or ERK1/2 phosphorylation (b), cells were pretreated
(15 min) with selective receptor antagonists (300 nM candesartan for AT1R or 1 μM PD123319 for AT2R) and subsequently treated with selective
agonists (100 nM angiotensin II for AT1R and/or 300 nM CGP-42112A for AT2R). Values are the mean ± S.E.M. of 5 independent experiments
performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for statistical analysis. Signaling
output was the dependent variable and the different treatments were the independent variables. (&p < 0.05 versus CGP-42112A treatment; *p <
0.05, **p < 0.01, ***p < 0.001 versus forskolin treatment in cAMP determinations or versus vehicle treatment (basal) in pERK determinations)
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red label was markedly increased in activated cells, as
shown in Fig. 5c and in the bar graph of Fig. 5d indicating
that AT1/2Hets expression increases in activated microglia.
We then performed cAMP level determination and ERK1/
2 phosphorylation assays in resting and activated micro-
glial cells. The functionality of AT1R, AT2R, and/or
AT1/2Hets in resting cells was very low. But in cAMP
assays, pretreatment with candesartan potentiated AT2R
Fig. 5 AT1R-AT2R heteromer functionality in microglial primary cultures treated with LPS and IFN-γ. a–c Expression of AT1R/AT2R heteromers in
primary microglial cultures were determined by PLA, which was performed using specific primary antibodies against AT1 and AT2 receptors
(confocal microscopy images (stacks of 3 consecutive planes) show heteroreceptor complexes as red clusters and Hoechst-stained nuclei (blue)).
Scale bar: 20 μm. d Bar graph showing the percentage of red dots/cell respect non-treated cells; mean ± S.E.M of counts in 5–7 different fields (n
= 5; **p < 0.01; Student’s t test versus the control condition). e, f Microglial cultures were incubated for 48 h in the absence (left) or in the
presence (right) of 1 μM LPS and 200 U/mL IFN-γ. Microglial cells were pretreated (15 min) with selective receptor antagonists (300 nM
candesartan for AT1R or 1 μM PD123319 for AT2R receptors) and subsequently with the specific agonists (100 nM angiotensin II for AT1R and 300
nM CGP-42112A for AT2R receptors). cAMP (e-f) and ERK1/2 phosphorylation (g-h) were subsequently measured. Values are the mean ± S.E.M. of
5 independent experiments performed in triplicates. One-way ANOVA followed by Bonferroni’s multiple comparison post-hoc test were used for
statistical analysis. Signaling output was the dependent variable and the different treatments were the independent variables. (+p < 0.05 versus
Ang II treatment in pERK determinations; and *p < 0.05, **p < 0.01, ***p < 0.001; versus forskolin treatment in cAMP measurements or versus
vehicle treatment (basal) in pERK measurements)
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induced signaling, and PD123319 potentiated AT1R func-
tionality (Fig. 5e, g). In contrast, the angiotensin-receptor-
mediated signaling was more robust in LPS + IFN-γ acti-
vated cells (Fig. 5f, h). In cAMP assays, the agonist of the
two receptors reduced the forskolin-induced levels of this
second messenger, although receptor costimulation did
not lead to any additive effect. As it occurred in HEK-
293T cells and neuronal primary cultures, antagonist pre-
treatments potentiated the partner receptor signal. On the
other hand, the agonist of any of the two receptors acti-
vated the MAPK signaling pathway, while simultaneous
stimulation completely blunted the ERK1/2 phosphor-
ylation effect in activated microglia. In this signaling
pathway, antagonists blocked the cognate receptor and
did not potentiate the activation of the partner receptor
in the heteromer. Taken together, these results indicate
that AT1/2Hets are significantly expressed in activated
microglia showing the same properties than those
displayed in heterologous system.
Expression AT1/2Hets in the striatum of parkinsonian and
dyskinetic rats
Striatal sections of naïve and of 6-OH-dopamine hemile-
sioned rats, treated or not with L-DOPA and divided
into L-DOPA/dyskinetic or resistant to L-DOPA-induced
dyskinesia were prepared as described in methods. PLA
assays were performed simultaneously and in identical
conditions to detect the occurrence and the amount of
AT1/2Hets. A representative image of each of the condi-
tions is shown in Fig. 6a–d, while quantitation is shown
in the form of bar graph in Fig. 6e. Whereas the amount
of AT1/2Hets was negligible in the non-lesioned stri-
atum, the lesioned one displayed more receptor clusters.
L-DOPA/dyskinetic animals showed a two-fold increase
if compared with the ipsilateral hemisphere of lesioned
rats. Remarkably, animals resistant to L-DOPA-induced
dyskinesia had a circa 10-fold increase in the amount of
AT1/2Hets (compared to control, non-lesioned hemi-
sphere). These results show that, in this specific PD
Fig. 6 AT1R-AT2R heteromer expression in brain striatal sections of Parkinson’s disease (PD) rat model. a–d PLA assays in striatal sections from the
6-OH-dopamine PD rat model, non-lesioned (a), lesioned (b), and lesioned plus chronically treated with L-DOPA and either lacking (c) or
displaying (d) dyskinesias. Confocal microscopy images (stacks of 3 consecutive planes) show heteroreceptor complexes as red clusters and
Hoechst-stained nuclei (blue). Scale bar: 20 μm. e Bar graph showing the percentage of red dots/cell. Data are the mean S.E.M . of counts in 9–12
different fields per animal (n = 4 per group). One-way ANOVA followed by Bonferroni’s post-hoc multiple comparison tests were used to
compare the red dots/cell values. The number of clusters (r) was the dependent variable and the four animal groups treatments were
independent variables (***p < 0.001; versus lesioned condition, ++p < 0.01; versus L-DOPA non-dyskinesia condition)
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model, of maximal dopaminergic denervation similar to
that observed in advanced stages of the disease, there is
striatal expression of the heteromer that is increased upon
L-DOPA administration. Remarkably, a much higher in-
crease in expression was found in L-DOPA-treated
animals that did not become dyskinetic.
Discussion
Details of peripheral RAS have been instrumental to de-
velop a successful therapy to combat hypertension. The
knowledge of RAS in the CNS is still fragmentary but
with repercussions in dopaminergic neurotransmission
and potential in PD and/or PD therapy-related dyskine-
sias. One of the added values of any future PD interven-
tion based in central RAS is the safety of angiotensin
receptor antagonists that have been used for decades in
hypertensive patients. While no double-blind placebo
controlled clinical trials have been designed, epidemio-
logical studies addressing the risk of hypertensive pa-
tients taking angiotensin receptor antagonists have been
performed. The fact that not all the drugs are able to
cross the blood-brain barrier complicates data analysis.
Anyhow, some of the reported results appear promising
and using ß-blockers as a control and 65,001 hyperten-
sive patients for > 4 years [34] showed that the use of
certain antihypertensives (angiotensin receptor blockers
included) associates with reduced PD risk. The still un-
solved question is whether such drugs may be of benefit
in improving symptoms, avoiding L-DOPA-induced
dyskinesias and/or in delaying the progression of the
disease.
First of all, it has been described that the global effects
of angiotensin on AT1 and AT2 receptors are opposite.
In several tissues, overactivity of the AT1 receptor has
been linked to aging-related pro-inflammatory changes
([16]; Labandeira-Garcia et al., [29, 30]). Different mech-
anisms have been proposed to explain counteracting ef-
fects of AT2R on AT1R signaling (see [43, 44], and [59]
for review). Although the issue is complex, the expres-
sion of AT2R in brain suggests a relevant role in the
regulation of neuroinflammation. On the one hand, as
earlier indicated, the two angiotensin receptors may
interact leading to receptor heteromers with particular
properties such as regulating SERCA activity [14, 48].
On the other hand, several heteromers formed by angio-
tensin receptors have been described. Among other
examples [58], it has been reported that apelin and AT1
receptors interact and that the resulting heteromers
mediate the apelin inhibition of AT1R-mediated actions.
MAS protooncogene, the novel player in RAS research,
rescues a defective AT1R, likely by forming heterodimers
[55]. The discovery of interaction between AT1R and the
most abundant receptor in the CNS, namely the canna-
binoid CB1 receptor, has led to hypothesize that these
functional units may lead to pathogenic actions when
Ang II is produced. However, the potential toxicity was
studied in hepatic cells in relation to ethanol consump-
tion but it was not assayed in neuronal cell models [53].
The AT1R may form complexes with a variety of adren-
ergic receptors [4, 21], although their relevance to CNS
physiology seems scarce. Less data are available for the
AT2R receptor that may interact (in the periphery) with
MAS and with bradykinin B2 receptors [1, 35, 44, 63]. In
addition, AT1/2Hets may form dimers that may eventu-
ally interact with MAS or with bradykinin B2 receptors
in cells in which three of these receptors are expressed
together [10, 54]. One of the relevant results in this
study is the demonstration in a rat model of microglial
AT1/2Hets expression and its upregulation correlating
with PD and with ulterior treatment with L-DOPA, the
most extended therapeutic agent in PD [9, 24, 42].
What is relevant for PD pathophysiology and disease
progression is to delay the death of the approximately 30%
nigral dopaminergic neurons that are left at the time of PD
diagnosis. Glia in general, and microglia in what concerns
to neuroinflammation, are key to preserve neurons from
death. AT1Rs have been proposed as targets to reduce
chronic neuroinflammation [26, 27, 50] as that occurring
in PD. The general idea is that activation of the AT1R is
detrimental, for instance by a microglia-mediated enhance-
ment of neuronal loss in status epilepticus induced in rats
[60]. In a previous study performed in the SN of rats we
showed that angiotensin-induced Rho-kinase activation
was involved in NADPH-oxidase activation, which, in turn,
was involved in angiotensin-induced Rho-kinase activation
[51]. In addition, a prevention of astrocyte activation and
promotion of hippocampal neurogenesis has been attrib-
uted to AT1R blockade and subsequent prevention of
NFкB and MAP kinase signaling and activation of Wnt/β-
catenin signaling [7]. In our experimental conditions
performed with already activated striatal microglia, MAP
kinase signaling is suppressed by combined treatment with
AT1 and AT2 receptor agonists. In the retina, AT1R activa-
tion results in regulating microglial activation thus suggest-
ing that Ang II may have important implications in
diabetic retinopathy [46]. To our knowledge, the expres-
sion of AT1/2Hets in retinal cells has not been addressed
yet. In agreement with the occurrence of a RAS opposite
arm consisting of AT2R (also of Mas receptor) (Laban-
deira-Garcia et al., [29, 30]), AT2R activation attenuates
microglial activation in an autoimmune encephalomyelitis
rodent model [62]. Activation of the receptor is neuropro-
tective in a model of ischemia induced in conscious rats
[37]. Similarly, the report by Bennion et al. [6] proves that
AT2R activation in neurons and glial cells affords long-
term neuroprotection in stroke, by both direct and indirect
mechanisms. Recent studies show that the receptor
prevents/attenuates pro-inflammatory microglial activity
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via protein phosphatase 2A-mediated inhibition of protein
kinase C [8].
To our knowledge, the AT1-bradikinin B2 heteroreceptor
complex was the first to be associated to a peripheral-
affecting disease. In fact, the expression of the heteromer
was increased thus mediating a higher Ang responsiveness
in preeclampsia, a disease that markedly alters blood pres-
sure in pregnancy [2]. The heteromer physiological func-
tion involves diverse signaling pathways and a variety of
cells events such as phosphorylation of c-Jun terminal kin-
ase and enhanced production of nitric oxide and a second
messenger, cGMP [1]. An unbalanced proportion of AT1-
bradikinin B2 receptor heteromers alters activation of
cognate G-proteins and receptor desensitization [3, 64]. We
have collected data on differential expression of dopamine-
receptor-containing heteromers in PD and the conclusion
is that very often the expression of heteromers is altered in
one or different stages of the disease. Usually, the expres-
sion of those heteromers in dyskinesia is lower than in PD
animals treated with L-DOPA but not displaying dyskine-
sias. Hence, this is the first example in which the already
enhanced expression of heteromers in parkinsonian condi-
tions is further increased in animals that were not rendered
dyskinetic by L-DOPA treatment. These results are relevant
as antagonists of angiotensin are considered as having
potential to both improve PD symptoms and minimize L-
DOPA-induced dyskinesias.
As in any other study focused on a neurodegenerative
disease, there are a number of limitations. Among them
we are extrapolating to “adult” cells using primary cells
obtained from fetuses of neonates. Although this is a
common procedure because the procedure of isolation
of primary neural cells from adult animals is not opti-
mized, a note of caution is needed. Another limitation of
our study is the variety of neural cell types. It is a chal-
lenge to know the relative expression of receptors in
projection neurons, in choline acetyltransferase (ChAT),
parvalbumin (PV), calretinin (CR), or nitric oxide syn-
thase interneurons and in astroglia and microglia, which
may be at different degrees of activation depending on
the disease status. Furthermore, receptor functionality in
response to a given receptor ligand may vary from cell
to cell [17] and at onset of disease when comparing
naïve versus L-DOPA-treated individuals.
But in any case, pharmacological manipulation of RAS
components presents potential in PD (Labandeira-Garcia
et al., [29, 30]). One of the relevant findings in this paper
is the insensitivity of AT2R to agonist treatment of
striatal neurons. Indeed, those neurons express both
Ang receptor types as previously demonstrated [19].
However, it is more remarkable that it becomes func-
tional in the presence of candesartan. There are few
examples of similar findings and a recent one consists of
progressive decrease of adenosine A2A receptor
functionality upon coexpression of another adenosine re-
ceptor, A2B, and formation of A2A/A2B heteroreceptor com-
plexes. This phenomenon is due to allosteric inter-
protomer interactions in the heteromer, i.e., the presence of
one receptor blocks the signaling of the partner receptor in
the complex [23]. Interestingly, the presence of an antagon-
ist could make, as in the case of Ang receptor heteromers
in striatal neurons, appear AT2R functionality back. There-
fore, AT1R antagonists in these neurons may achieve two
benefits, which are repressing the detrimental actions medi-
ated by the AT1R while making that the AT2R becomes
functional and provides the benefits associated to its activa-
tion. Furthermore, in terms of looking for interventions to
prevent PD disease progression, there is enough informa-
tion to agree that microglial cells may be key if there is a
way to skew the physiology to acquire the M2 neuroprotec-
tive phenotype. On the one hand, neuronal alpha-synuclein
produces an upregulation of AT1R while increasing in
microglia the proportion of pro-inflammatory M1 versus
neuroprotective M2 markers; accordingly, it is suggested
that antagonists already used in hypertension and able to
cross the blood-brain barrier may be repurposed for the
therapy of PD [52]. On the other hand, microglial AT2Rs,
constituent in AT1/2Hets, show promise as (i) they are
upregulated in both parkinsonian conditions and in L-
DOPA-induced dyskinesias and (ii) their activation is seem-
ingly neuroprotective. Remarkably, AT1/2Hets do not show
cross-antagonism, a property displayed by many hetero-
mers and that would lead to a therapeutic dead end in
terms of neuroprotection; instead, the antagonist of one re-
ceptor releases the brake on activation of the partner recep-
tor. Taken together, the opposite action of AT1 and AT2
receptors, their expression in microglia, and the marked
upregulation of AT1/2Hets lacking cross-antagonism but
displaying antagonist-mediated cross-potentiation suggest
that interventions aimed at antagonizing central AT1Rs to
potentiate AT2R-mediated actions may be beneficial in PD.
Further experimental effort is required to identify the cell
types expressing the heteromer in the different parkinson-
ian conditions and to prove the functionality of the hetero-




The present study demonstrates that AT1 and AT2 recep-
tors form AT1/2Hets that are expressed in cells of the cen-
tral nervous system. AT1/2Hets are novel functional units
with particular signaling properties. Importantly, the coacti-
vation of the two receptors in the heteromer reduces the
signaling output of angiotensin. Remarkably, AT1/2Hets,
which are expressed in both striatal neurons and microglia,
show a cross-potentiation, i.e., candesartan, the antagonist
of AT1 increases the effect of AT2 receptor agonists. In
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addition, the level of expression in the unilateral 6-OH-
dopamine lesioned rat PD model increases upon L-DOPA
treatment and is maximal in those animals that do not
become dyskinetic.
Importance and relevance of the study reported
These findings reported are potentially important because
they indicate that boosting the action of neuroprotective
AT2 receptors using an AT1 receptor antagonist constitutes
a promising therapeutic strategy in PD. The strategy may
consist of designing AT1R receptor antagonists able to
readily cross the blood-brain barrier and effective in releas-
ing the brake on the AT2 receptor. The fact that SARS-
CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as
receptor, that ACE2 interacts with angiotensin receptors,
that some COVID-19 patients with severe symptoms
display a “cytokine storm” driven by macrophages and/or
suffer neurological alterations, adds interest to the present
work on the RAS system in microglia.
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